Xenograft models have been used to evaluate human antibody-based treatments; however, evaluation of immune-mediated regulation of anti-EGFR antibody (Cetuximab) effects are limited since human EGFR-dependent tumors cannot grow in immune-competent wild type mice and there is no mouse tumor cell line that responds to cetuximab. This evidence concerns the gene EGFR and neoplasm.